Q2 2019 13F Holders as of 30 Jun 2019
-
Type / Class
-
Debt / NOTE 0.750% 5/1
-
Unit price / market price
-
$0.8632
-
Total 13F principal
-
$726,411,131
-
Principal change
-
+$720,284,131
-
Total reported value
-
$626,631,807
-
Number of holders
-
49
-
Value change
-
+$621,342,068
-
Number of buys
-
48
Institutional Holders of LIGAND PHARMACEUTICALS INC - NOTE 0.750% 5/1 as of Q2 2019
As of 30 Jun 2019 LIGAND PHARMACEUTICALS INC - NOTE 0.750% 5/1 had 49 institutional bondholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions held a total of $726,411,131 principal (par value or face value) of the bond of the company.
Largest 10 bondholders included Allianz Asset Management GmbH, CANYON CAPITAL ADVISORS LLC, ADVENT CAPITAL MANAGEMENT /DE/, CAMDEN ASSET MANAGEMENT L P /CA, STEELHEAD PARTNERS LLC, CITADEL ADVISORS LLC, WOLVERINE ASSET MANAGEMENT LLC, STATE STREET CORP, Polar Capital LLP, and Davidson Kempner Capital Management LP.
This table shows 49 bond principal holders of the security as of 30 Jun 2019.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Principal |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.